Introduction
In recent years, radioimmunotherapy (RIT) with ␤ − particleemitting radionuclides such as 131 I and 90 Y targeting the CD20 antigen on B cells in the treatment of non-Hodgkin's lymphoma (NHL) has provided the most compelling human clinical data for the success of RIT. 1, 2 For example, an overall response rate of 100% was observed in preliminary studies using 131 I-labeled anti-B1 in previously untreated patients with stage 3 or 4 follicular NHL. 3 A 72% overall response rate was achieved with a single dose of 90 Y-Y2B8 anti-CD20 monoclonal antibody (mAb) administered in an outpatient setting. 4 Additional promise has been demonstrated using mAbs that target the major histocompatibility complex class II allele HLA-DR10, 5 Ig idiotype (Id), 6 CD20, 7, 8 and CD22. 9 CD19 is a 95 kDa B lineage-specific membrane glycoprotein, which can be found on Ͼ95% of B cell lymphomas and chronic lymphocytic leukemia (CLL) and, unlike CD20, it is found also on acute lymphocytic leukemia (ALL) cells. 10 It is rarely lost during the process of neoplastic transformation, but disappears upon differentiation to mature plasma cells; it is not expressed on hematopoietic stem cells, nor on normal tissues outside the B lineage; it is not shed into the circulation. Hence, CD19 may provide an alternative target to CD20 for RIT of B cell neoplasms. Historically, CD19 has been largely overlooked as a target for conventional 131 I RIT because the antigen rapidly internalizes upon binding of antibodyresulting in catabolism and release of 131 I. 11 The problem of the 131 I dehalogenation and metabolism after internalization of antibody can be circumvented by using residualizing radiolabels, such as radioactive metals. 12 It has been demonstrated that radiometals such as 90 Y, an essentially pure beta particle emitting radionuclide, are retained longer intracellularly. 13 In comparison to CD20, the CD19 antigen is expressed more broadly on normal as well as malignant B cells. The CD20 antigen is a 33-35 kDa integral membrane phosphoprotein. It is expressed slightly later in B cell differentiation than the CD19 antigen and is also lost at the plasma cell stage. The CD20 antigen is generally expressed in larger numbers on the surface of the cell than CD19.
14 Recent data demonstrate that CD19 expression is maintained despite loss of CD20 expression following treatment with anti-CD20 antibodies. 15 Although RIT of human lymphoma in patients has in general been successful in obtaining both partial and complete responses lasting several months or longer, the treatment of human lymphoma cell xenografts in murine models is a more difficult undertaking. 16, 17 This is probably due to (1) the rapid growth of the aggressive, high grade Burkitt's tumors that are available and (2) the small geometry of the animal that makes effective, selective delivery of the ␤ − particles to the tumor without reaching the maximum tolerated dose of radiation to the bone marrow difficult. Tumor responses are typically of short duration in these model systems, but they still provide a useful model to study different RIT agents in a comparative manner.
In this pre-clinical study, we developed two 90 Y constructs using an anti-CD19 antibody (B4) and an anti-CD20 antibody (C2B8) to treat human lymphoma. We have characterized these constructs in vitro and compared the efficacy of 90 Ylabeled anti-CD19 antibody (B4) and anti-CD20 antibody (C2B8) to treat lymphoma in a mouse xenograft model of Ramos Burkitt's lymphoma.
Materials and methods

Cell lines, antibodies and reagents
The CD19 and CD20-positive human malignant Ramos cell line and the CD19 and CD20-negative Molt-4 or HL60 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained as exponentially growing cultures in RPMI 1640 medium supplemented with P+S, l-glutamine, 10% FBS (2% RS) at 37°C in 5% carbon dioxide.
Anti-B4 (ImmunoGen, Boston, MA, USA) is a murine IgG1 mAb directed against the CD19 antigen. IDEC-C2B8 (IDEC Pharmaceuticals, San Diego, CA, USA) is a mouse-human chimeric IgG1 anti-CD20 mAb. HuM195, a humanized IgG1 mAb against the CD33 antigen, was used as the negative control antibody.
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The SCN-CHX-A"-DTPA (2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid) is a bifunctional chelating agent provided by the National Cancer Institute (Bethesda, MD, USA). 19 111 In (a ␥-emitting radionuclide, t 1/2 = 2.8 days) chloride and 90 Y (a ␤ − particle emitting radionuclide E max = 2.28 MeV, t 1/2 = 2.67 days) chloride were obtained from NEN Life Science Products (North Billerica, MA, USA).
Antibody conjugation and radiolabeling
Conjugation of SCN-CHX-A"-DTPA to the antibodies was conducted in metal-free conditions using an Amicon continuous dialysis apparatus similar to that reported by Nikula et al. 20 Briefly, 20 mg of B4 (or C2B8) was first dialysed against 10 mM EDTA/50 mM HEPES/150 mM NaCl buffer at pH 8.4 to remove any possible metal ions existing in the antibody solution and then dialysed against the buffer without EDTA. A 50-fold molar excess of SCN-CHX-A"-DTPA to antibody was added and allowed to react with the antibody overnight at ambient temperature. Following this reaction, the antibody solution was dialysed against pH 7.0 20 mM NaAc/150 mM NaCl buffer. B4 or C2B8 immunoconjugate was recovered and the concentration was determined by the absorbance at 280 nm. The average number of chelates per antibody was determined by a spectrophotometric method. 21 Immunoconjugates were radiolabeled with 111 In and 90 Y radionuclides. Either radiometal in 0.05 M HCl was diluted with 0.2 M HCl and buffered with 3 M NH 4 Ac to pH 4.5. An aliquot of l-ascorbic acid (150 g/l) was added as a radioprotection agent. An aliquot containing 0.1-0.5 mg of the construct was added for radiolabeling and incubated at ambient temperature for 20 min. The reaction was quenched by the addition of 10 mM EDTA. Radiolabeled antibody constructs were purified using P10-desalting column (Bio-Rad Laboratories, Hercules, CA, USA) and 1% human serum albumin (HSA). The reaction yield and purity of purified product were determined using ITLC and HPLC methods. 20 
Immunoreactivity
The immunoreactivity of the 111 In-labeled antibody constructs was determined by incubating approximately 2-3 ng of purified radiolabeled antibody in 0.05-0.10 ml total volume with 10 × 10 6 Ramos cells or 5 × 10 6 Molt-4 or HL60 (negative control) in the presence of 2% rabbit serum to avoid nonspecific binding. After 30 min incubation at 0°C, the cells were Leukemia separated from supernatant by centrifugation and then washed twice with PBS. The activity associated with cells and in the supernatant and wash was counted using a Packard Cobra Gamma Counter (Packard Instrument Co., Meriden, CT, USA) with a 15-550 keV energy window and the percentage of the immunoreactivity was calculated.
Competition radioimmunoassay
Comparison of antigen antibody avidity (K d ) between the native antibody and its corresponding CHX-A"-DTPA construct was done by competition with 111 In-radiolabeled constructs. Increasing amounts of each cold mAb or its construct were incubated with 2 × 10 5 Ramos cells and 25 ng/ml of 111 In antibody in 0.20 ml of RPMI for 1 h at 0°C. Cells were washed three times in RPMI and counted. To avoid nonspecific and Fc receptor binding, the assays were done in the presence of 2% rabbit serum. Samples were run in duplicate, and the relative avidity of binding was estimated by comparison of mAb concentrations where unlabeled competitor yields 50% inhibition of binding. In-labeled antibody plus excess cold antibody. Ramos cells (0.10 ml) in suspension at a concentration of 2 × 10 6 cell/ml were added to 0.10 ml of a serial dilution of the 111 In-labeled antibody solution. This was incubated with cells for 90 min with mixing. Cells were washed with 2 ml ice-cold PBS three times. The radioactivity associated with cell pellets and in the wash solution was counted using the gamma counter.
CD19 and CD20 expression on Ramos cells and antibody binding to the cells
Therapeutic studies
Animals were studied under the guidelines of institutionally approved protocols. Female athymic nude mice (National Cancer Institute, Frederick, MD, USA), weighing 19-23 g and 6-8 weeks old were injected with 7 × 10 6 Ramos tumor cells intramuscularly in the left hind leg. After visible tumor appeared, the perpendicular dimensions of tumors were measured by vernier calipers every 1-3 days and the tumor volume was recorded as the maximum section area of length (cm) times width (cm). A therapy study was conducted to compare the therapeutic efficacy of 90 Y-radiolabeled C2B8 and B4 in comparison to controls. Mice with an average tumor size of 0.8 cm 2 were divided into groups containing similar tumor size (n = 6 per group) and treated as follows: (1) Y-C2B8 (7.5 Ci/g); (4) 0.020 mg of unlabeled C2B8; or (5) untreated growth controls. A second therapy study was performed to determine the specificity of 90 Y-radiolabeled specific vs nonspecific radiolabeled antibodies. On day 13 following tumor xenograft the (see above), mice were divided into four groups and treated as follows (1) Y-HuM195 (n = 5). In all groups, the animal weights were obtained two to three times weekly. The mice were examined for signs of toxicity, such as petecchiae, severe weight loss or skin damage. All treat-ments were well tolerated. The mice were killed when the tumor size exceeded 3 cm 2 or mice were severely ill. The significance of the difference in animal survival in the treatment and control groups was determined using a KaplanMeier survival analysis with a log-rank test.
Results
Antibody conjugation and radiolabeling
The bifunctional chelating agent, SCN-CHX-A-DTPA, has been selected as the moiety to bind Y was 97 ± 2% (n = 11). After purification, radiochemical purity was 98 ± 2% (n = 11) for both antibodies. The immunoreactivity of radiolabeled B4 and C2B8 was 68 ± 7% (n = 5) and 42 ± 17% (n = 6), respectively.
Antigen densities on lymphoma Ramos cells and avidities of antibodies bound to the cells
The relative densities of the B cell surface antigens recognized by the anti-CD19 and anti-CD20 antibodies labeled with 111 In and the avidities of the antibodies binding to target antigens were determined using a Scatchard analysis (Figure 1 ). Mean CD19 expression on Ramos cells was 19 810 ± 1350 sites/cell and a K d of the anti-B4 to CD19 antigen was 0.29 ± 0.02 nM, whereas CD20 expression was 62 440 ± 4810 sites/cell with a K d of 3.69 ± 0.03 nM. The expression of CD20 on Ramos cells was about three-fold more than CD19 expression, but the affinity of anti-B4 to CD19 antigen was about 10-fold greater than affinity of C2B8 to CD20 surface antigen.
Competition radioimmunoassay comparing native antibody and its CHX-A"-DTPA construct was performed to determine whether the modification of antibody with CHX-A"-DTPA changed binding properties of the antibodies. No significant differences between antibody and construct were found (not shown).
Therapy studies
The first therapy study was designed to compare radiotherapeutic effects of 90 Y-labeled anti-CD19 and anti-CD20 antibodies to native anti-CD20 antibody and growth control groups. After measurable tumor appeared, mice were divided into groups with an average tumor size of 0.8 cm In B4 and C2B8 binding assay and (b) the Scatchard analysis on Ramos (B4 data represented with squares; C2B8 data represented with circles). progress 9 days after the treatments. In contrast, the tumor in the two control groups showed no regressions during the same time period (Figure 2 A second therapy study was performed to determine the specific cytotoxicity in vivo of 90 Y-radiolabeled antibodies, demonstrating that the killing was due to selective delivery of the radiation to the tumor by the lymphoma-specific antibody rather than nonspecific delivery or to circulating radioisotope. In this study, 
Discussion
The clinical success of RIT for B cell NHL can be explained by many factors. There are well-defined lymphoma-associated antigens for which multiple monoclonal antibodies are available; the lymphoma cells are (1) readily accessible to radiolabeled antibody in the blood, marrow and lymph nodes; (2) are highly radiosensitive; and (3) the long ranged ␤ − particle crossfire from adjacent antigen-positive tumor cells allows eradication of both antigen-negative tumor cells and killing of antigen-positive cells residing deep within or adjacent to the tumor. In addition, the native anti-CD20 antibodies have intrinsic anti-lymphoma activity that adds efficacy to the RIT. Furthermore, nonspecific ␤ − particle irradiation from the circulating radiolabeled antibody may contribute to cytotoxicity.
Clinical RIT trials in lymphoma have concentrated on anti-CD20 antibodies using 131 I and 90 Y with non-myeloablative doses, 22 or myeloablative doses with bone marrow transplantation or stem cell support. 23 The clinical results are impressive, resulting in two antibody conjugates ready for marketing approval from the FDA. RIT using HLA-DR or CD22 as targets for the radioimmunotherapy of NHL are also in earlier phases of clinical trial and the safety and efficacy of these agents is being demonstrated. The CD19 antigen, however, has been largely overlooked as a target for conventional RIT because the antigen rapidly internalizes upon binding of antibody. 24 Modulation appears to be dependent on IgG isotype as well. 25, 26 Concerns were raised that internalization would result in catabolism and release of radionuclides such as 131 29 Among B cell antigens that are possible targets for RIT, CD19 has the advantage of having the widest expression on neoplasms of B cell origin, including acute and chronic lymphocytic leukemia and non-Hodgkin's lymphomas. Because of its internalization after binding to antibody, CD19 has been intensively studied as a target for immunotoxin therapy of lymphoma. 30, 31 The most extensive trials utilized anti-B4-bR, which comprises the mouse IgG1 mAb anti-B4 conjugated to a blocked ricin moiety. Anti-B4 binds CD19-bearing B cells with high affinity and has demonstrated impressive anti-tumor activity in numerous studies performed in vitro and in immunocompromised mice. Intriguing evidence of clinical activity was obtained within the settings of NHL, acute and chronic leukemias (ALL and CLL), and multiple myeloma. However, the ricin moiety imparted unfavorable safety, pharmacologic, and immunogenic properties that compromised its therapeutic use. The characteristics of the CD19 antigen system and the data derived from these pre-clinical and clinical studies have provided impetus to develop anti-CD19 radioimmunotherapies for treatment of NHL, ALL and CLL.
We compared the biology and the therapeutic activity of this anti-CD19 construct to a similar one directed against CD20, which is currently the most widely used target and which is the antigen target of the FDA approved C2B8 antibody. We characterized the biochemistry of the constructs and their use in the therapy of human lymphoma xenografted in mice. The data indicated that 90 Y-labeled B4 compares favorably to 90 Y-C2B8 in the treatment of mice bearing human lymphoma. In this model of a rapidly growing, advanced Burkitt's lymphoma, the unconjugated C2B8, at the low-dose level of 0.020 mg seems to have no significant therapeutic effect despite activity at high doses in other systems. Unlabeled B4 has not been reported to have therapeutic effects against established tumors. Specific therapeutic effects were observed with both the 90 Y-C2B8 and 90 Y-B4. Control treatments with equivalent doses of radiation on an irrelevant antibody demonstrated that just the radiation therapy was due to specific targeting of the radiolabeled antibody rather than from nonspecific irradiation from circulating irrelevant labeled antibody.
As expected, CD19 and CD20 differed in their expression on the cell surface. The expression of CD20 on Ramos cells was three times greater than the expression of CD19. Although CD20 has been reported not to modulate quickly or efficiently, our data indicated that after 111 In-C2B8 bound to Ramos cells, a significant fraction of the radioactivity could not be stripped off from the cells by acid, suggesting it has been internalized by the cell. The amount of the activity modulated was time dependent (not shown). Hence, the 111 In-C2B8-CD20 antibody-antigen complex appears to undergo some modulation as well. B4 and C2B8 differ greatly in their binding affinity; the affinity of 111 In-B4 to Ramos cells is almost 10 times greater than 111 In-C2B8. In addition, the immunoreactivity of radiolabeled B4 is greater than that of C2B8. Therefore, the therapeutic advantages of B4 in this model may be related to the increased uptake and retention of radioactivity delivered by 90 Y-B4 as compared to 90 Y-C2B8 due to its greater immunoreactivity, larger antigen binding affinity, and more rapid internalization into Ramos cells.
In conclusion, the characteristics of the CD19 antigen system, the previous clinical data with CD19 immunotoxins, and the results of this comparative study here, suggest that CD19-targeted RIT warrants further study as a possible treatment of B cell neoplasms.
